Among the 18 evaluable patients (15 with NSCLC) for Programmed Cell Death Ligand 1 (PD-L1) expression, around 80% of them had tumors with negative or intermediate expression of PD-L1. The gene discussed is CD274; the disease is non-small cell lung carcinoma.